Moleculin Biotech (MBRX)
(Delayed Data from NSDQ)
$4.77 USD
+0.13 (2.80%)
Updated May 31, 2024 04:00 PM ET
After-Market: $4.87 +0.10 (2.10%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Moleculin Biotech, Inc. [MBRX]
Reports for Purchase
Showing records 21 - 40 ( 162 total )
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
1Q23: Annamycin Trials Going Well, Ample 2023 Data Flow, Funded Into 3Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
CR in 1st Dose Cohort of Annamycin/Cytarabine in AML, 2nd Cohort Begins
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Annamycin Data Show Favorable PK, Distribution, And Efficacy
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
4Q22: Annamycin Trials Going Well, Ample 2023 Data Coming, Funds Into 3Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
1st Annamycin Combo Therapy AML Patient Dosed, STS-LM Trial Data Imminent
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Re-Releases Top-Line Phase 1 AML Data, But Adds Patient & Safety Details
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Adds Clinical Trial Sites in Italy for Its European Rel/Ref AML Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Promising 80% ORR in Final Phase 1 Annamycin Dose Cohort in Rel/Ref AML
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
3Q22: Clinical Pipeline Progressing Well, Funded Into 2H24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J